# Perrigo Company plc (PRGO)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/PRGO/primer

## Business Model

---
source: coverage-next-full
ticker: PRGO
step: "01"
title: Business Overview — Perrigo Company plc
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company at a Glance

Perrigo Company plc is the **world's largest manufacturer of over-the-counter (OTC) store-brand (private-label) consumer healthcare products**. Headquartered in Dublin, Ireland, and listed on the NYSE, Perrigo operates as the hidden engine behind the store-brand OTC medicine shelves at Walmart, CVS, Walgreens, Target, Costco, Kroger, and Amazon. When a consumer reaches for the CVS-brand ibuprofen instead of Advil, there is a high probability it was manufactured by Perrigo.

The company pivoted decisively in 2021 by divesting its Rx pharmaceutical generics business to become a pure-play **consumer self-care** company. The subsequent acquisition of HRA Pharma in 2022 added a branded international OTC portfolio — shifting the mix toward branded products in Europe while maintaining the dominant private-label position in the Americas.

#### What Perrigo Does

Perrigo's core value proposition is straightforward: it develops, manufactures, and distributes store-brand equivalents of branded OTC products at materially lower prices, giving retailers high-margin, lower-cost alternatives to national brands. This "value brand" model benefits retailers (higher private-label margins vs. branded resale) and consumers (20–30% savings on therapeutically equivalent products).

Secondary value: In international markets (primarily Europe), Perrigo owns branded OTC products — not private-label — that compete directly with Haleon, Kenvue, and Reckitt product lines.

#### Business Segments

##### Consumer Self-Care Americas (CSCA) — ~55–67% of Revenue
The flagship segment. CSCA is the largest private-label OTC manufacturer in the United States. It manufactures and distributes store-brand equivalents across categories:

| Category | Example Products | National Brand Equiv. |
|----------|-----------------|----------------------|
| Analgesics | Store-brand ibuprofen, acetaminophen | Advil, Tylenol |
| Cough / Cold / Allergy | Store-brand DXM, guaifenesin, loratadine | NyQuil, Mucinex, Claritin |
| Gastrointestinal | Store-brand antacids, laxatives, anti-diarrheal | Tums, Dulcolax, Imodium |
| Smoking Cessation | Store-brand nicotine patches, gum | Nicorette, NicoDerm |
| Infant Nutrition | Store-brand infant formula | Similac, Enfamil (Abbott, Reckitt) |
| Women's Health | Opill® (OTC oral contraceptive) | First-mover in new OTC category |
| Eye / Ear Care | Store-brand eye drops, ear wax kits | Visine, Debrox |

**Opill®** (norgestrel 0.075mg) is noteworthy: the first-ever FDA-approved daily oral contraceptive available OTC without a prescription. Approved July 2023, launched early 2024. Perrigo holds the exclusive OTC right, representing a rare branded growth vector within CSCA.

**Infant Formula** (~$360M revenue, ~8–9% of total): Perrigo is the largest US private-label infant formula manufacturer (a market segment not supplied by Abbott or Mead Johnson). The 2022 Abbott recall created a temporary windfall. A strategic review was announced in November 2025 to evaluate divestiture or other options.

##### Consumer Self-Care International (CSCI) — ~33–45% of Revenue
A branded OTC portfolio in Europe and Australia, significantly enlarged by the HRA Pharma acquisition. Key brands:

| Brand | Category | Primary Markets |
|-------|----------|----------------|
| Compeed® | Blister/wound care | Europe-wide |
| Solpadeine® | Analgesic (codeine-containing) | UK, Ireland |
| Coldrex® | Cold/flu remedy | Central/Eastern Europe |
| Mederma® | Scar treatment | Europe |
| ellaOne® | Emergency contraceptive (HRA) | Europe |
| Plan B® | Emergency contraceptive (HRA, US) | US/Americas |
| Dermacosmetics | Skincare | Europe (under divestiture review) |

HRA Pharma also brought a pipeline of Rx-to-OTC switch projects — a strategic growth avenue for branded consumer health across Europe.

#### Transformation Story (2021–2026)

Perrigo's recent history is defined by two decisions of opposing nature:

**Rx Divestiture (2021):** Sold the prescription generics business, refocusing on consumer OTC. This simplified the business and reduced generic pharma pricing/volume risk. It also generated cash, temporarily improving the balance sheet.

**HRA Pharma Acquisition (2022):** Paid ~€1.8B for HRA Pharma, funded predominantly with debt. This added branded European OTC and reproductive health products (ellaOne, Plan B) but substantially levered the balance sheet (net leverage jumped to ~5x). Post-acquisition integration has been the dominant strategic focus since.

The net result: Perrigo is now a mid-complexity consumer health company with a leading private-label US franchise, a branded European portfolio, and a leveraged balance sheet in need of repair.

#### Key Facts

| Metric | Value (May 2026) |
|--------|----------------|
| Market Cap | ~$1.58B |
| Annual Revenue | ~$4.25B (FY2025) |
| Employees | ~9,000–10,000 |
| Listed | NYSE (PRGO); Euronext Dublin |
| Incorporated | Ireland |
| Fiscal Year | Calendar year (Dec 31) |
| Dividend | $1.16/share (~10% yield) |
| Net Leverage | ~4.5x adj. EBITDA (FY2025 est.) |

## Financial Snapshot

---
source: coverage-next-full
ticker: PRGO
step: "04"
title: Financial Snapshot — 3-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot

#### Annual P&L Summary (USD millions)

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Commentary |
|--------|--------|--------|--------|--------|-----------|
| **Revenue** | $4,452 | $4,656 | $4,373 | $4,253 | Declining since FY2023 peak |
| **Gross Profit** | $1,455 | $1,680 | $1,543 | $1,495 | — |
| **Gross Margin %** | 32.7% | 36.1% | 35.3% | 35.2% | Recovered from HRA-dilution low |
| **Operating Income (GAAP)** | $79 | $152 | $113 | -$1,122 | FY2025 devastated by impairments |
| **EBIT Margin (GAAP)** | 1.8% | 3.3% | 2.6% | -26.4% | Not meaningful; impairment-driven |
| **Adj. EBITDA** | ~$418 | ~$511 | ~$439 | n/m | Adjusted basis used by company |
| **Adj. EBITDA Margin** | ~9.4% | ~11.0% | ~10.0% | est. ~10–11% | Approximately stable core profitability |
| **Net Income (GAAP)** | -$141 | -$13 | -$172 | -$1,425 | Perennial GAAP losses; impairments + interest |
| **EPS Diluted (GAAP)** | -$1.04 | -$0.09 | -$1.25 | -$10.29 | FY2025 massive impairment |
| **Adj. EPS (Non-GAAP)** | n/a | n/a | est. ~$2.60 | est. ~$2.50 | Management's preferred earnings metric |

**Key Note on GAAP vs. Adjusted:** Perrigo's GAAP financials are persistently negative due to (1) non-cash amortization of acquired intangibles from HRA Pharma and other M&A, and (2) recurring restructuring/impairment charges. The FY2025 GAAP net loss of -$1,425M was driven primarily by ~$1.3B+ in non-cash goodwill and intangible impairments (Q4 2025 and Q1 2026 charges) tied to the CSCI portfolio revaluation following the Dermacosmetics divestiture announcement and weaker-than-expected performance. Management and analysts focus on **adjusted EPS** (excluding amortization, impairments, restructuring) for normalized earnings power. Adjusted EPS of ~$2.50 in FY2025 vs. GAAP EPS of -$10.29 illustrates the magnitude of these adjustments.

#### Revenue Trend Analysis

Revenue grew from $4,139M in FY2021 to a peak of $4,656M in FY2023 (+12.5% over 2 years), benefiting from:
- HRA Pharma consolidation (added ~$500–600M of CSCI revenue from mid-2022)
- Abbott infant formula recall market share gains (2022)
- Post-COVID cough/cold volume recovery

The subsequent decline to $4,373M (FY2024) and $4,253M (FY2025) reflects:
- CSCA softness: competitive pricing pressure and infant formula volume normalization
- CSCI headwinds: unfavorable currency, Dermacosmetics under review
- Absence of 2022's non-repeating infant formula windfall

FY2026 consensus: ~$4,140M (-2.7% further decline), as divestitures partially offset Opill ramp and Project Energize cost savings.

#### Gross Margin Analysis

Gross margin collapsed to 32.7% in FY2022 (HRA integration costs, supply chain inflation, working capital build) then recovered to 36.1% in FY2023. FY2024–FY2025 stabilization at ~35% represents the new normalized level. Management targets 22–24% adjusted EBIT margin (implying incremental operating leverage above the current ~35% gross margin level). Adjusted EBIT margin in FY2024 was roughly 10–11%, leaving a gap vs. target.

#### Cost Structure

| Cost Line | Est. % of Revenue | Commentary |
|-----------|------------------|-----------|
| COGS | ~65% | Manufacturing, raw materials, packaging |
| SG&A | ~15–18% | Marketing (CSCI branded), corporate overhead |
| R&D | ~3–5% | Primarily Rx-to-OTC switch development (HRA heritage) |
| Amortization | ~6–8% | HRA intangibles ($3.2B acquired intangible base) |
| Restructuring | ~1–2% | Project Energize ongoing |

The dominant intangible amortization burden (~$250–350M/year) is the primary driver of the GAAP vs. adjusted divergence.

#### Interest Expense

With ~$3.6B in total debt, interest expense is substantial:
- FY2024: ~$210–230M (estimated at ~5.5–6% blended rate on mix of fixed senior notes and floating revolver)
- FY2025: similar level — ~$200–225M

Interest expense effectively absorbs approximately half of adjusted EBITDA (~$450M), leaving FCF generation thin relative to debt level.

#### Adjusted EBITDA Trend

| Year | Adj. EBITDA | Adj. EBITDA Margin | Commentary |
|------|-------------|-------------------|-----------|
| FY2022 | ~$418M | ~9.4% | HRA integration drag |
| FY2023 | ~$511M | ~11.0% | Best recent performance |
| FY2024 | ~$439M | ~10.0% | Revenue decline + pricing pressure |
| FY2025 | ~$400–440M (est.) | ~9.5–10.3% | Project Energize saves begin; volume headwinds |
| FY2026E | ~$450–480M (est.) | ~10.9–11.6% | Energize savings ramp + divestitures |

Management is targeting a path to 22–24% adjusted EBIT margin, roughly double the FY2024–FY2025 level, through Project Energize ($140–170M gross savings by end-2026) and portfolio optimization.

#### EPS Bridge (GAAP to Adjusted)

Starting from GAAP EPS of -$1.25 (FY2024):
- Add back: ~$250–300M amortization of acquisition-related intangibles
- Add back: ~$50–100M restructuring/impairment charges
- Add back: ~$30–50M non-cash share-based comp and other items
- Tax impact on adjustments
- Approximate **adjusted EPS ≈ $2.50–2.70**

This bridge is essential for evaluating whether the business is generating real economic returns. The ~$280M+ in annual amortization from HRA is a non-cash charge that distorts GAAP earnings for 10–15 years post-acquisition.

#### Three-Year P&L Scorecard

| KPI | FY2022 | FY2023 | FY2024 | Trend |
|-----|--------|--------|--------|-------|
| Revenue Growth | +7.6% | +4.6% | -6.1% | Declining |
| Gross Margin | 32.7% | 36.1% | 35.3% | Recovering/Stable |
| Adj. EBITDA Margin | ~9.4% | ~11.0% | ~10.0% | Volatile |
| FCF ($M) | $211 | $304 | $245 | Declining |
| GAAP Net Loss ($M) | -$141 | -$13 | -$172 | Persistently negative |
| Net Debt ($B) | ~$3.5 | ~$3.3 | ~$3.1 | Gradually declining |
| Dividend Covered by FCF? | Yes | Yes | Yes (barely) | Thin coverage |

## Recent Catalysts

---
source: coverage-next-full
ticker: PRGO
step: "12"
title: Catalysts — Near-Term Drivers & Bull/Bear Cases
created: 2026-05-29
---

### Step 12 — Catalysts

#### Catalyst Timeline (2026–2027)

| Catalyst | Expected Timing | Bull Impact | Bear Impact |
|---------|----------------|-------------|-------------|
| Dermacosmetics sale closure | H1 2026 | ~$350M debt paydown → leverage ~4.2x | Lower than expected proceeds → less deleveraging |
| Infant formula strategic review conclusion | Q2–Q3 2026 | Sale at 1.2x rev → ~$430M proceeds | Buyer not found; retained at declining revenue |
| Project Energize savings delivery | FY2026 (full year) | $80–100M net savings flow → adj. EPS upside | Savings delayed; cost inflation offsets |
| Opill ramp Q2/Q3 2026 | Quarterly | Revenue inflection visible; new OTC category | Low consumer awareness; slow adoption |
| Q2 2026 earnings + leverage update | Aug 2026 | Adj. EBITDA expansion + leverage ratio moving toward 3x | Revenue miss + margin miss + guidance cut |
| FY2026 guidance raise | Q2–Q3 2026 | Market re-rates from deep value to recovery story | Guidance cut triggers credit/dividend concerns |
| Credit facility health (covenant compliance) | Ongoing | Continued compliance; no issues | Covenant stress triggers lender restrictions |
| Dividend review (cut/maintain) | Board decision | Maintain signals confidence (near-term positive) | Cut signals cash flow stress (short-term negative, long-term positive) |
| New Rx-to-OTC switch approval (EU pipeline) | 2027–2028 | High-multiple branded OTC category created | Regulatory rejection; R&D capital stranded |

#### Near-Term Catalysts (12 Months)

##### 1. Dermacosmetics Divestiture Completion (~$350M)
**Status:** Proposed sale announced July 2025; expected close H1 2026 (subject to regulatory approval)
**Impact:** Proceeds designated for debt reduction
- Best case: €327M (~$350M) received; net debt falls from ~$3.1B to ~$2.75B; leverage ratio improves ~0.4–0.5x
- This is the largest near-term debt reduction catalyst and has the highest probability of occurring (management-controlled)

##### 2. Infant Formula Strategic Review Outcome
**Status:** Announced November 2025; review ongoing; conclusion expected mid-2026
**Impact:** ~$360M revenue (~8–9% of total) at below-average margins
- Best case: Sale at 1.0–1.5x revenue (~$360–540M) significantly reduces leverage
- Base case: Sale at ~0.8–1.0x revenue; modest proceeds but removes a low-quality revenue stream
- Bear case: No qualified buyer; business retained; drag continues; strategic review overhang lingers

##### 3. Project Energize Savings Realization
**Target:** $140–170M gross annualized savings by end of FY2026 ($80–130M net)
**Impact:** First full-year benefit appears in FY2026 adj. EBITDA
- If ~$100M net savings flow through in FY2026: adj. EBITDA could reach $530–540M vs. ~$440M in FY2024
- This improvement would flow directly into FCF and reduce leverage ratio by ~0.3–0.4x organically
- **Highest-probability positive catalyst** — management has been specific and credible about this program

##### 4. Opill Revenue Ramp
**Status:** Launched OTC in early 2024; building distribution and awareness through 2025–2026
**Impact:** Modest near-term but meaningful optionality
- FY2026 Opill revenue estimate: $50–100M+ (immature; limited analyst consensus)
- Long-term: If oral contraceptive OTC market reaches $500M+ revenue category, Opill could become $200–400M business with strong margins
- Visibility-creating events: quarterly disclosure of new product revenue, distribution milestones

##### 5. Q2/Q3 2026 Earnings Inflection
Following Dermacosmetics divestiture close + Project Energize savings + Opill ramp:
- First quarter showing YoY adj. EBITDA margin expansion would be a sentiment catalyst
- Market re-pricing from "distressed value" to "restructuring success" could compress discount multiple
- Key metric: Does adj. EPS guidance midpoint rise above $2.40 (current consensus high-end)?

#### Negative Catalysts to Monitor

1. **Dividend cut announcement:** A dividend cut, while ultimately credit-positive, would be a stock price negative short-term and signal FCF stress
2. **Covenant breach or refinancing complications:** Any signal of lender stress would be severely negative
3. **FDA Warning Letter at major facility:** Immediate operational and financial impact; share price collapse risk
4. **Infant formula review fails to find buyer:** Retained drag + capital tied up in low-return asset
5. **CSCA pricing further compressed by retailer consolidation:** Margin miss triggers leverage concern spiral

---

**Bull Case**
- Project Energize delivers $100–130M net savings by end-FY2026, Dermacosmetics proceeds ~$350M reduce leverage to ~4x, and Opill emerges as a $150M+ revenue category-creating product; the combined effect drives adj. EBITDA from ~$440M toward $580–600M by FY2027, leverage hits <3x ahead of schedule, and the market re-rates from 8x to 12x adj. EBITDA, implying equity value of $15–22/share.
- Infant formula sale at ~1.2x revenue (~$430M) provides a second major debt paydown catalyst in H2 2026, accelerating the deleveraging timeline and potentially funding a dividend cut-to-reinvest or a credit upgrade.
- Consumer trade-down tailwind from persistent inflation drives CSCA private-label market share gains, inflecting organic revenue from -3% to +2%, while the 10% dividend yield attracts income investors and provides a valuation floor.

**Bear Case**
- Project Energize savings are offset by ongoing CSCA pricing concessions and input cost re-inflation, leaving adj. EBITDA stuck at $400–420M and leverage structurally above 4x; lenders add covenant restrictions that limit operational flexibility.
- The infant formula strategic review fails to find a buyer at acceptable terms, and the Dermacosmetics sale closes at a significant discount to the €327M ask, delivering <$200M in net proceeds; the combination leaves leverage elevated and raises dividend sustainability questions that management eventually cannot avoid.
- Opill faces unexpectedly slow consumer adoption (awareness, access, cost barriers) and becomes a rounding-error revenue contributor, while a new competitor pursues FDA approval for an OTC contraceptive, eliminating Perrigo's first-mover premium; PRGO stock tests new 52-week lows below $9 on leverage + growth fears.

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/prgo
- Full research API: GET /api/v1/research/PRGO/memo
- Coverage universe: /stocks